We are live on ! Find out more
NRXPW

NRX Pharmaceuticals Warrant
NRXPW

Delisted

NRXPW was delisted on the 22nd of May, 2026.

Back to rankings

19 hedge funds and large institutions have $747K invested in NRX Pharmaceuticals Warrant in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

21% more capital invested

Capital invested by funds: $616K → $747K (+$131K)

12% more funds holding

Funds holding: 17 → 19 (+2)

Holders
19
Holders Change
+2
Holders Change %
+11.76%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$33.2K
2
PAMP
Polar Asset Management Partners
Ontario, Canada
+$30.9K
3
KPF
K2 Principal Fund
Ontario, Canada
+$17.9K
4
CI
Cowen Inc
New York
+$11.9K
5
GCL
Glazer Capital LLC
New York
+$3.38K

Top Sellers

Rank Fund Capital Flow
1
WCMNY
Westchester Capital Management (New York)
New York
-$22K
2
BCM
Bluefin Capital Management
New York
-$18K
3
LIM
Longfellow Investment Management
Massachusetts
-$8K
4
BI
Bulldog Investors
New Jersey
-$1.42K

NRXPW Hedge Fund Activity: Q2 2019 in Review

19 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q2 2019, worth a combined $747K — up 21% from $616K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NRXPW positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $33.2K. The largest seller was Westchester Capital Management (New York), exiting entirely with an estimated $22K sold.

  • 19 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q2 2019, up from 17 in Q1 2019.
  • Funds reported $747K of NRX Pharmaceuticals Warrant stock for Q2 2019, up 21% quarter-over-quarter.
  • 4 funds opened new NRX Pharmaceuticals Warrant positions in Q2 2019 and 2 closed out, a net change of +2 holders.
  • The largest NRX Pharmaceuticals Warrant buyer in Q2 2019 was Hudson Bay Capital Management, an estimated $33.2K added.
  • The largest NRX Pharmaceuticals Warrant seller in Q2 2019 was Westchester Capital Management (New York), an estimated $22K sold.

Based on aggregated 13F filings for Q2 2019.